查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球重组 DNA 技术市场-2022-2029
市场调查报告书
商品编码
1140722

全球重组 DNA 技术市场-2022-2029

Global Recombinant DNA Technology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年重组 DNA 技术市场价值 1567.5 亿美元。预计在预测期内（2022-2029 年）的复合年增长率为 4.80%。

重组 DNA 技术涉及将携带感兴趣基因的 DNA 插入基因组。它通过拼接来自两个不同物种的 DNA 分子并将它们插入宿主生物体来创建新的遗传组合。新的基因组合包含来自基因组中未发现的多种来源的遗传物质。结果，生产了转基因生物和产品。转基因生物（例如微生物、动物和植物）已被证明可以提高产品产量并增强适应性，从而更好地生存。

几家公司正在使用重组 DNA 技术生产胰岛素、follistim、人类生长激素、单克隆抗体、人类白蛋白、疫苗、基因治疗和其他治疗剂。它还用于生产转基因作物、克隆动物、生物农药、生物燃料和其他产品。

市场动态

重组 DNA 技术的进步推动市场增长

市场正在见证开发高效诊断工具和疗法的技术进步。 Bac-to-Bac 桿状病毒表达系统的引入提供了一种在昆虫细胞中有效生产携带感兴趣基因的重组桿状病毒的方法。与耗时的限制性□克隆相比，Bac-to-Bac 桿状病毒表达系统加速了克隆反应。 CRISPR技术是一种可以修改DNA序列并改变基因功能的技术。它用于各种目的，例如纠正遗传缺陷、治疗和预防疾病传播以及改良农作物。正在引入生殖细胞基因疗法，其中将 DNA 移植到产生卵子和精子的细胞中，这些细胞是体内的生殖细胞。这种治疗可有效纠正导致代代相传疾病的基因突变。体细胞基因疗法是一种将 DNA 引入体内组织的治疗方法。这种治疗针对的是不会代代相传的身体细胞。

预计基因工程产品开发的资金和投资将在预测期内推动市场增长。

一些组织、协会和实验室正在增加对重组产品开发的资金和投资。例如，2020 年 3 月，流行病防范创新联盟 (CEPI) 与 Novavax 和牛津大学签署了一项合作协议，投资 440 万美元，以快速开发针对 COVID-19 的重组疫苗产品。根据协议条款，CEPI 将向 Novavax 提供初始资金，为 I 期临床试验做准备。牛津大学将帮助製造临床前和 I 期试验所需的疫苗原材料。 2020 年 7 月，美国卫生与公众服务部 (HHS) 和国防部 (DoD) 授予赛诺菲和葛兰素史克 21 亿美元，用于开发和製造基于重组蛋白的 COVID-19 疫苗。卫生与公众服务部 (HHS) 和国防部 (DoD) 将为“曲速行动”提供资金。

与使用转基因产品相关的道德问题阻碍了市场增长

使用转基因产品存在一些道德问题。例如，基因工程产品是否与天然产品具有生物等效性，基因工程蛋白质会引起免疫原性反应，从而限制它们的使用。重组产品的使用正在篡改基因组。动物和人类系统之间免疫易感性的差异已证明是灾难性的结果。抗体 TGN1412 在类风湿性关节炎和 B 细胞慢性淋巴细胞白血病患者中的 Tegenero 试验揭示了其毒性。种系基因疗法最终将通过去除所谓的坏基因来减少人类基因库。由于基因治疗费用高昂，只有富人才能受益。基因疗法的普及可能会降低社会对与众不同的人的接受程度。对于基因治疗以增强身高、智力和运动能力等基本人类特征也存在伦理问题。

COVID-19 影响分析

由于 COVID-19 大流行，全球重组 DNA 技术市场经历了巨大的增长。几家生物製药公司专注于使用重组 DNA 技术开发疫苗以预防 COVID-19。随着感染 COVID-19 的人数增加，用于开发 COVID-19 重组疫苗的研发活动正在加强。该管道由多种病毒载体、核酸疫苗和正在为 COVID-19开发的抗原呈递细胞组成。病毒载体疫苗是使用重组 DNA 技术克隆具有降低的致病性的重组病毒和编码病毒抗原的基因。蛋白质疫苗由从病毒或病毒感染细胞中纯化的蛋白质、重组蛋白质和病毒样颗粒组成。

多个机构、组织、研究机构和公司正在参与联合研究，以开发针对 COVID-19 传染病的重组疫苗。例如，2020 年 4 月，赛诺菲与葛兰素史克签订了一项合作研究协议，以开发 COVID-19 的辅助疫苗。根据协议，赛诺菲将提供基于重组 DNA 技术的 S 蛋白 COVID-19 抗原。葛兰素史克将提供其经过验证的大流行佐剂技术。这可以减少单次注射所需的疫苗蛋白量，从而可以生产更多疫苗并保护更多人。

流行病学

慢性病是全球死亡率和发病率的主要原因。根据美国疾病控制和预防中心 (CDC) 的数据，每 10 名成年人中就有 6 人患有慢性病。据说十分之四的人患有两种或两种以上的慢性疾病。心脏病、癌症、慢性肺病、中风、阿尔茨海默病、糖尿病和慢性肾病是最常见的慢性疾病。吸烟、营养不良、缺乏运动、过度饮酒和其他疾病会增加患慢性病的风险。根据美国糖尿病协会的数据，美国约有 3420 万人患有糖尿病。其中，约 160 万人患有 1 型糖尿病。

市场细分

重组DNA技术市场有望以医疗领域为主

按产品类型，由于重组 DNA 技术在药品生产中的广泛应用，预计医疗领域将占重组 DNA 技术治疗市场的最大份额。重组 DNA 技术是生产新药、更安全或更有效的常规药物以及与常规药物相同的物质的技术。在医学领域，它们分为治疗药物、人体蛋白质和疫苗。重组 DNA 技术用于生产人类蛋白质，用作诊断工具和治疗剂，并可治疗多种遗传相关疾病。多种重组蛋白，如重组激素、干扰素、白细胞介素、生长因子、肿瘤坏死因子、凝血因子、溶栓剂和□，可用于治疗糖尿病等疾病。侏儒症、心肌梗塞、充血性心力衰竭、脑出血、多发性硬化症、中性粒细胞减少症、血小板减少症、贫血症、肝炎、类风湿性关节炎、哮喘、克罗恩病等。使用重组 DNA 技术製造的疫苗基于编码来自特定病毒病原体的蛋白质的生物构建体的表达。这些疫苗由实验室合成的蛋白质或糖蛋白亚基製成。

预计表达系统部分将在预测期内表现出最快的增长率

按成分，市场分为表达系统和克隆载体。表达系统对于所选宿主细胞中的蛋白质表达至关重要。开发高效的蛋白质表达系统已成为全球范围内的大规模活动。该市场主要由几种表达系统的可用性主导，例如细菌表达系统、酵母表达系统、桿状病毒表达系统和哺乳动物表达系统。表达系统的选择取决于许多因素，包括目标蛋白特性、预期用途、蛋白产量和成本。酵母表达系统是一种新的外源蛋白表达系统，它结合了原核和真核表达系统的特点。酵母表达系统广泛用于基因工程领域。在哺乳动物细胞表达系统中表达的重组蛋白通过质粒转染或病毒载体感染来表达。越来越多的研究评估植物作为生产转基因产品的表达系统的潜力。

区域分析

北美在重组 DNA 技术的全球市场中占有最大份额。

北美地区在 2019 年占据全球重组 DNA 技术市场的最大市场份额，因为该地区在製药、农业、工业和研究领域广泛采用重组 DNA 技术。随着慢性病的兴起，重组DNA技术在疾病预防、治疗和管理方面的应用正在兴起。由于存在许多生物製药製造商，美国的市场份额最高。先进的重组 DNA 技术在兽药、转基因作物和生物农药的开发中的使用越来越多。研究人员还使用重组 DNA 技术来改进用于生物燃料生产的生物质。

生物製药的研发活动也很活跃。多家公司已与研究机构、组织和团体合作开发生物製药。例如，2020 年 2 月，赛诺菲与美国卫生与公众服务部防备和应对助理部长办公室下属的生物医学高级研究与发展局 (BARDA) 合作开发重组疫苗新型冠状病毒。签署。根据协议，赛诺菲将使用无卵重组 DNA 平台生产其 COVID-19疫苗。 BARDA 将提供专业知识和重新分配的资金来支持疫苗开发。 2019 年 12 月，赛诺菲与生物医学高级研究与发展局 (BARDA) 建立合作伙伴关係，在美国建立最先进的设施，用于生产佐剂重组大流行性流感疫苗。

预计亚太地区将在预测期内以最快的复合年增长率增长

由于开发重组 DNA 技术产品的市场参与者越来越多，亚太地区是全球重组 DNA 技术市场中增长最快的地区。由于拥有熟练且廉价的劳动力，一些公司正在将其製造基地转移到亚太地区。人类健康、食品和农业对重组和转基因产品的需求不断增加。

公司正在使用转基因作物来提高作物产量、降低食品和药品生产成本、减少对农药的使用需求、提高营养成分和食品质量以及增强对病虫害的抵抗力。我们专注于改进重组 DNA 技术用于作物生产。重组 DNA 技术在药学、基因治疗、疫苗设计和生物修復方面的选择性改进正在取得进展。一些组织、协会和研究机构正在资助和投资重组 DNA 技术在医疗保健、食品和农业中的使用。

竞争格局。

重组 DNA 技术市场是一个分散的市场，市场参与者众多。 F. Hoffmann-La Roche Ltd, Biogen, Amgen Inc, Novartis AG, Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S, Sanofi, Merck KGaA, GlaxoSmithKline plc, Thermo Fisher Scientific, Inc 拥有很大的市场份额 成为播放器。领先的公司采用了多种增长战略，例如产品发布、产品批准、合併、许可、收购和合作伙伴关係，为重组 DNA 技术市场的全球增长做出了贡献。例如：

合併和合作。

2021 年 5 月 21 日，Biogen 宣布已与 Ginkgo Bioworks 就开发新型基因疗法製造平台的许可协议进行合作。

2020 年 1 月 2 日，安进宣布与百济神州结成战略联盟，以扩大其在中国的肿瘤业务。

产品发布和批准

2021 年 8 月 3 日，Ameghan 宣布在 Holly Springs 建设一个价值 5.5 亿美元的生物製剂製造工厂。

2019 年 4 月 1 日，金斯瑞推出了基于 CRISPR 的基因编辑的单链 DNA 服务。这项新服务将为研究人员提供用于基于 CRISPR 的基因插入以及最终用于癌症研究和治疗的基因治疗、细胞治疗、转基因治疗的高质量、纯 ssDNA，这将有助于加速遗传动物模型的开发。

收购

2020 年 10 月，Proteintech 收购了 Cameroid、单域抗体或纳米抗体製造商 ChromoTek。 ChromoTek 是用于突破性研究发现的纳米抗体高性能重组试剂的市场领导者。

合作伙伴关係

2020 年 8 月，Novavax 与武田製药有限公司建立合作伙伴关係，在日本开发、製造和商业化用于 COVID-19 的 NVX-CoV2373。 NVX-CoV2373 是一种稳定的预融合蛋白，采用 Novavax 的重组蛋白纳米颗粒技术开发，包括 Novavax 的专有 Matrix-M 佐剂。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按组件划分的市场细分
  • 按应用划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 技术进步
      • 生物製药的兴起
    • 限制因素
      • 监管、科学和道德问题
      • 与使用重组 DNA 技术相关的风险
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

    • 医疗
      • 治疗药
      • 人体蛋白质
      • 疫苗
    • 非医疗
      • 生物作物
      • 特种化学品
      • 其他

第 8 章按组件

    • 表达系统
      • 哺乳动物
      • 细菌
      • 酵母
      • 桿状病毒/昆虫
      • 其他
    • 克隆载体

第 9 章。按应用程序

  • 食品和农业
  • 健康与疾病
  • 环境
  • 其他

第 10 章，最终用户

  • 生物技术公司、製药公司
  • 学术和政府研究机构
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 13 章公司简介

  • 孟山都公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • F. Hoffmann-La Roche Ltd
  • Biogen
  • Amgen Inc
  • Novartis AG
  • Eli Lilly and Company
  • GenScript
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Sanofi
  • Merck KGaA
  • Profacgen
  • Biocon
  • GlaxoSmithKline plc.
  • Cibus
  • Horizon Discovery Group plc
  • New England Biolabs
  • Thermo Fisher Scientific, Inc.（LIST NOT EXHAUSTIVE）

第14章 DataM

简介目录
Product Code: DMPH2798

Market Overview

Recombinant DNA Technology Market was valued at USD 156.75 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 4.80% during the forecast period (2022-2029).

Recombinant DNA technology includes the insertion of the DNA into the genome with the gene of interest. It produces new genetic combinations by joining the DNA molecules from two different species and inserted into the host organism. The new genetic combination includes the genetic material from multiple sources not found in the genome. It results in the production of genetically modified organisms and products. Genetically modified organisms such as microorganisms, animals, and plants have shown enhanced product yield and increased adaptability for better survival.

Several companies are using recombinant DNA technology for producing insulin, Follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, gene therapy and other therapeutics. It is also used for producing genetically modified crops, cloned animals, biopesticides, biofuel, and other products.

Market Dynamics

Technology Advancement of Recombinant DNA Technology is Driving the Growth of the Market

The market is witnessing technological advancement for developing efficient diagnostic tools and therapeutics. The introduction of the Bac-to-Bac baculovirus expression systems provided an efficient method to produce recombinant baculovirus with desired genes in insect cells. Bac-to-Bac baculovirus expression systems have accelerated the cloning reaction compared to the restriction enzyme cloning which consumes a lot of time. CRISPR technology can alter DNA sequences and modify gene function. It is used in various applications such as correcting genetic defects, treating and preventing the spread of diseases and improving crops. There is increasing adoption of germline gene therapy to transfer the DNA into the cells that produce reproductive cells, eggs or sperm, in the body. This therapy is beneficial for correcting disease-causing gene variants that can be passed from generation to generation. Somatic gene therapy is used for transferring the DNA into the body tissues. It targets the body cells that are not passed from generation to generation.

Increasing Funding & Investment for Development of Recombinant Products is Expected to Fuel the Market Growth over the Forecast Period

Several organizations, associations, and institutes are raising the funding & investment for developing recombinant products. For instance, in March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), had invested USD 4.4 million in collaboration agreements with Novavax, Inc. and The University of Oxford to rapidly develop recombinant vaccine products against COVID-19. Under the terms of the agreement, CEPI would provide initial funding to Novavax to enable preparations for phase I trials. The University of Oxford would support the manufacture of vaccine materials required for preclinical and phase I testing. In July 2020, the United States Departments of Health and Human Services (HHS) and Defense (DoD) awarded the funding of USD 2.1 billion to Sanofi and GlaxoSmithKline for the development and manufacturing of the recombinant protein-based COVID-19 vaccine. Health and Human Services (HHS) and Defense (DoD) would provide the funding for Operation Warp Speed.

Ethical Issues Regarding the Use of Recombinant Products is Hampering the Market Growth

There are several ethical issues are associated with the use of recombinant products. There are several concerns including whether the recombinant products are biologically equivalent to the natural product, and recombinant proteins can result in immunogenic reactions that could limit their use. The use of the recombinant product is tampering with the genome. Differences in immunological sensitivities in animal and human systems have demonstrated disastrous effects. TeGenero trial conducted for testing an antibody TGN1412 among the patients with rheumatoid arthritis and B-cell chronic lymphocyte leukaemia has shown the harmful effects. Germ-cell gene therapy would ultimately diminish the human gene pool by removing genes considered to be bad. Only rich people would be benefited due to the high cost of gene therapy. The widespread use of gene therapy can make society to least accept the people who are different. There are also ethical concerns regarding gene therapy for enhancing basic human traits such as height, intelligence, or athletic ability.

COVID-19 Impact Analysis

The global recombinant DNA technology market has witnessed drastic growth due to the COVID-19 pandemic as several biopharmaceutical companies are focusing on developing the vaccine by using recombinant DNA technology for the prevention of COVID-19. There is increasing research and development activities for developing the recombinant vaccine for COVID-19 with the rising number of people being affected by the COVID-19 infection. The pipeline comprised of several viral vectors, nucleic acid-based vaccines and antigen-presenting cells being developed for COVID-19. Viral vector vaccines are comprised of the recombinant virus that is attenuated to reduce its pathogenicity, and genes encoded with viral antigens are cloned using recombinant DNA techniques. Protein-based vaccines comprised of the protein purified from the virus or virus-infected cells, recombinant protein or virus-like particles

Several organizations, associations, institutes, and companies are entering into the collaboration for the development of a recombinant vaccine for COVID-19 infection. For instance, in April 2020, Sanofi had entered into the collaboration with GlaxoSmithKline plc to develop an adjuvanted vaccine for COVID-19. Under the terms of the agreement, Sanofi would contribute its S-protein COVID-19 antigen based on recombinant DNA technology. GlaxoSmithKline plc would contribute its proven pandemic adjuvant technology. This may be useful to produce more vaccine doses with the reduced amount of vaccine protein required per dose and thus protect more people.

Epidemiology

Chronic diseases are the leading cause of mortality and morbidity worldwide. According to the Centers for Disease Control and Prevention (CDC), around, 6 out of 10 adults are suffering from chronic diseases. Approximately, 4 out of 10 people develop two or more chronic diseases. Heart disease, cancer, chronic lung disease, stroke, Alzheimer's disease, diabetes, and chronic kidney disease are the most common chronic diseases. Tobacco consumption, poor nutrition, lack of physical activity, excessive alcohol use, and other disorders increase the risk of developing chronic diseases. According to the American Diabetes Association, approximately 34.2 million are suffering from diabetes in the United States. Out of these people, around 1.6 million are affected by type 1 diabetes.

Market Segment Analysis

The medical segment is expected to hold the largest share in the Recombinant DNA Technology market

By Product Type, the medical segment is anticipated to hold the largest share in the recombinant DNA technology treatment market owing to the higher adoption of recombinant DNA technology for producing pharmaceutical products. Recombinant DNA technology produces novel pharmaceutical products, safer or more effective versions of conventionally produced pharmaceuticals, and substances identical to conventionally made pharmaceuticals. The medical segment is classified as the therapeutic agent, human protein, and vaccine. Recombinant DNA technology is used to produce human proteins that can be used as diagnostic tools and therapeutics to treat various genetically linked diseases. Various recombinant proteins such as recombinant hormones, interferons, interleukins, growth factors, tumour necrosis factors, blood clotting factors, thrombolytic drugs, and enzymes are useful for the treatment of the diseases such as diabetes, dwarfism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anaemia, hepatitis, rheumatoid arthritis, asthma, Crohn's disease, and others. Vaccines produced by using recombinant DNA technology are based on the expression of biological constructs encoding proteins from specific viral pathogens. These vaccines are made of protein or glycoprotein subunits synthesized in the laboratory.

Expression System Segment is Anticipated to Grow at the Fastest Growth Rate over the Forecast Period

By component, the market is segmented into an expression system and cloning vector. Expression systems are essential for expressing the proteins within the chosen host cell. There is increasing development of efficient protein expression systems at a large scale across the globe. The market is dominated by the availability of several expression systems such as bacteria expression system, yeast expression system, baculovirus expression system and mammalian expression system. The choice of the expression systems depends on various factors such as target protein property, intended application, protein yield and cost. The yeast expression system is the new exogenous protein expression system that contains the characteristics of both prokaryotic and eukaryotic expression systems. There is high usage of the yeast expression system in genetic engineering. The recombinant proteins expressed in the mammalian cell expression system includes the use of plasmid transfection and viral vector infection. There is increasing research for evaluating the potential of plants as the expression system for the production of genetically modified products.

Geographical Analysis

North America region holds the largest market share global Recombinant DNA Technology market

North America region is dominating the global recombinant DNA technology market accounted for the largest market share in 2019 due to higher adoption of the recombinant DNA technology in medicines, agriculture, industries, and research. There is increasing recombinant DNA technology for the prevention, treatment, and management of diseases with the increasing prevalence of chronic diseases. The United States accounts for the highest market share due to the presence of a large number of biopharmaceutical manufacturing companies. There is rising usage of advanced recombinant DNA technologies for developing veterinary products, genetically modified crops, and biopesticides. Researchers are also using recombinant DNA technology to alter the biomass for improving its use for biofuel production.

There is increasing research and development activities for biopharmaceuticals. Several companies are entering into collaboration with institutes, organizations, and associations for developing biopharmaceuticals. For instance, in February 2020, Sanofi had entered into collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the United States Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response for the development of the recombinant vaccine for novel coronavirus. Under the terms of the agreement, Sanofi would use its egg-free, recombinant DNA platform to produce a vaccine for novel coronavirus. BARDA would provide the expertise and reallocated funds to support the vaccine's development. In December 2019, Sanofi had entered into the collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to establish the state-of-the-art facilities in the United States for the production of an adjuvanted recombinant vaccine for the influenza pandemic.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is the fastest-growing region in the global recombinant DNA technology market as there is an increase in market players developing recombinant DNA technology products. Several companies are shifting their manufacturing base to the Asia-Pacific region due to the availability of skilled and cheap labourers. There is rising demand for recombinant and genetically modified products for human health, food and agriculture.

Companies are focusing on improving the recombinant DNA technology for the production of genetically modified crops to increase crop yields, reduce costs for food or drug production, reduce the need for use of pesticides, enhance the nutrient composition and food quality, resistance to pests and disease. There is growing penetration of recombinant DNA technology for providing selective improvements in pharmaceutics, gene therapy, vaccine design and bioremediation. Several organizations, associations, and institutes are raising the funding & investment for the use of recombinant DNA technology for healthcare, food and agriculture.

Competitive Landscape:

The recombinant DNA technology market studied is a fragmented market with a large number of market players. F. Hoffmann-La Roche Ltd, Biogen, Amgen Inc, Novartis AG, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, Sanofi, Merck KGaA, GlaxoSmithKline plc., and Thermo Fisher Scientific, Inc are the market players with the significant market share. The major players are adopting several growth strategies such as product launches, product approvals, mergers, licensing, acquisitions, and collaborations, contributing to the growth of the recombinant DNA technology market globally. For instance,

Mergers & Collaborations:

On 21st May 2021, Biogen announced it collaborated with Ginkgo Bioworks on a license agreement to develop a Novel Gene Therapy Manufacturing platform.

On 2nd January 2020, Amgen announced it has a strategic collaboration with BeiGene to expand its oncology presence in China.

Product Launch & Approvals:

On 3rd August 2021, Amegan Inc announced that it will build its Biologics Manufacturing Facility with 550 million USD in Holly Springs.

On 1st April 2019, GenScript launched a Single-stranded DNA Service for CRISPR-based Gene Editing. The new service offers researchers access to high-quality, pure ssDNA for CRISPR-based gene insertion, ultimately helping to accelerate the development of gene therapy, cell therapy, and transgenic animal models for cancer research and treatment.

Acquisition:

In October 2020, Proteintech acquired ChromoTek, a manufacturer of Camelid, single-domain antibodies i.e., nanobodies. ChromoTek is the market leader in nanobodies high-performance recombinant reagents for breakthrough research discoveries.

Partnership:

In August 2020, Novavax, Inc had entered into a partnership with Takeda Pharmaceutical Company Limited for the development, manufacturing and commercialization of NVX-CoV2373 for COVID-19 in Japan. NVX-CoV2373 is a stable, prefusion protein developed using the Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Component
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by End-User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements
      • 4.1.1.2. Rising of Biopharmaceutical Industry
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Regulatory, scientific, and ethical challenges
      • 4.1.2.2. Risk associated with use of Recombinant DNA Technology
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Medical*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.3. Therapeutic Agent
      • 7.3.1.4. Human Protein
      • 7.3.1.5. Vaccine
    • 7.3.2. Non-medical
      • 7.3.2.1. Biotech Crops
      • 7.3.2.2. Specialty Chemicals
      • 7.3.2.3. Other

8. By Component

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  • 8.3. Market Attractiveness Index, By Component Segment
    • 8.3.1. Expression System*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.3. Mammalian
      • 8.3.1.4. Bacteria
      • 8.3.1.5. Yeast
      • 8.3.1.6. Baculovirus / Insect
      • 8.3.1.7. Others
    • 8.3.2. Cloning Vector

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. Food and Agriculture*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Health and Disease
    • 9.3.3. Environment
    • 9.3.4. Others

10. By End-User

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.3. Market Attractiveness Index, By End-User Segment
    • 10.3.1. Biotechnology and Pharmaceutical Companies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Academic and Government Research Institutes
    • 10.3.3. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Monsanto Company*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. F. Hoffmann-La Roche Ltd
  • 13.3. Biogen
  • 13.4. Amgen Inc
  • 13.5. Novartis AG
  • 13.6. Eli Lilly and Company
  • 13.7. GenScript
  • 13.8. Pfizer Inc.
  • 13.9. Novo Nordisk A/S
  • 13.10. Sanofi
  • 13.11. Merck KGaA
  • 13.12. Profacgen
  • 13.13. Biocon
  • 13.14. GlaxoSmithKline plc.
  • 13.15. Cibus
  • 13.16. Horizon Discovery Group plc
  • 13.17. New England Biolabs
  • 13.18. Thermo Fisher Scientific, Inc. (LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us